Early data from Viking Therapeutics suggest an experimental injectable helped people retain most weight lost while using GLP‑1 drugs after switching to less‑frequent dosing. In a two‑part trial of 180 adults with obesity, every‑other‑week dosing preserved at least 90% of weight loss and monthly dosing preserved at least 80%, versus about 61% for placebo. The company says fewer injections could boost long‑term adherence as the drug moves into late‑stage trials.
Experimental Injectable Helps Patients Maintain Weight Loss With Fewer Injections
Experimental weight-loss shot helps patients keep weight off with fewer injections
Early results from Viking Therapeutics indicate an experimental injectable may help people keep most of the weight they lost on GLP‑1 medications even after switching from weekly injections to less‑frequent dosing.
Study Design and Results
In a two‑part trial of 180 adults with obesity, all participants began on weekly injections designed to produce weight loss. After the initial phase, subsets of participants were transitioned to reduced dosing schedules to test how well they maintained their weight loss.
Key findings: Participants switched to every‑other‑week injections retained at least 90% of the weight they had lost. Those moved to monthly injections retained at least 80% of their prior weight loss. By comparison, participants receiving placebo injections retained about 61% of their weight loss.
Why This Matters
Weight regain after reducing or stopping GLP‑1 therapy is a common concern. Viking Therapeutics says that a therapy requiring fewer injections could improve long‑term adherence and make it easier for patients to sustain benefits. The company has advanced the agent to large, late‑stage clinical trials to confirm these early findings.
Limitations: These are early results from a relatively small study. Larger, longer trials are needed to verify durability, safety, and real‑world effectiveness.
As research continues, clinicians and patients will watch for final results from the late‑stage studies and regulatory updates.
Help us improve.
